P22 Patient-level meta-analysis of efficacy and safety from STRIVE and ReSTORE: randomized, double-blinded, multicentre Phase 2 and Phase 3 trials of rezafungin in the treatment of candidaemia and/or invasive candidiasis

BACKGROUND: Rezafungin is a next-generation echinocandin in development for treatment of candidaemia and invasive candidiasis (IC) and for prevention of invasive fungal disease caused by Candida, Aspergillus and Pneumocystis spp. in blood and marrow transplantation. Rezafungin once-weekly (QWk) was...

Descripción completa

Detalles Bibliográficos
Autores principales: Soriano, A, Thompson, G R, Cornely, O A, Kullberg, B J, Kollef, M, Vazquez, J, Honore, P M, Bassetti, M, Pullman, J, Dignani, C, Das, A F, Sandison, T, Pappas, P G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848852/
http://dx.doi.org/10.1093/jacamr/dlac133.026

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848852/
http://dx.doi.org/10.1093/jacamr/dlac133.026

Ejemplares similares